Baxter International Inc. reported a net loss of $15 million for the first quarter of 2026, a reversal of the $126 million profit posted in the same period a year earlier. The loss translates to a basic earnings per share of $0.03, while adjusted earnings—excluding one‑time items—were $0.36 per share, beating analysts’ consensus of $0.31.
Revenue rose 3 % year‑over‑year to $2.701 billion, driven by growth in the Medical Products & Therapies segment, which generated $1.285 billion in revenue. The segment saw 2 % reported growth but a 2 % organic decline, reflecting pricing pressure and lower absorption rates. Healthcare Systems & Technologies added $705 million, flat reported growth, and Pharmaceuticals contributed $621 million, up 7 % reported growth.
Operating margins contracted, with the adjusted gross margin falling 500 basis points to 36.8 % and the adjusted operating margin shrinking 390 basis points to 7 %. The compression is largely attributable to higher tariff‑related costs, increased manufacturing expenses, and lower absorption rates that reduced the company’s ability to spread fixed costs over a larger volume.
Baxter reiterated its full‑year earnings guidance of $1.85 to $2.05 per share, maintaining the same range it set in the prior quarter. Management emphasized that the guidance reflects confidence in stabilizing the business and executing its turnaround strategy, while acknowledging that margin pressure and one‑time charges will continue to weigh on short‑term profitability.
The results were met with a positive market reaction, as investors highlighted the adjusted EPS beat and revenue growth as evidence of operational resilience. Analysts noted that the GAAP loss is largely driven by one‑time restructuring and regulatory compliance charges, and that the company’s ability to generate a positive adjusted EPS despite margin compression signals effective cost control and a favorable product mix.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.